ES2917982T3 - Método para tratar trastornos hepáticos - Google Patents

Método para tratar trastornos hepáticos Download PDF

Info

Publication number
ES2917982T3
ES2917982T3 ES15735507T ES15735507T ES2917982T3 ES 2917982 T3 ES2917982 T3 ES 2917982T3 ES 15735507 T ES15735507 T ES 15735507T ES 15735507 T ES15735507 T ES 15735507T ES 2917982 T3 ES2917982 T3 ES 2917982T3
Authority
ES
Spain
Prior art keywords
compound
formula
group
ester
liver
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15735507T
Other languages
English (en)
Spanish (es)
Inventor
Kazuko Matsuda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medicinova Inc
Original Assignee
Medicinova Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medicinova Inc filed Critical Medicinova Inc
Application granted granted Critical
Publication of ES2917982T3 publication Critical patent/ES2917982T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
ES15735507T 2014-01-10 2015-01-07 Método para tratar trastornos hepáticos Active ES2917982T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14/152,924 US8962687B2 (en) 2012-12-05 2014-01-10 Method of treating liver disorders
PCT/US2015/010479 WO2015105874A1 (en) 2014-01-10 2015-01-07 Method of treating liver disorders

Publications (1)

Publication Number Publication Date
ES2917982T3 true ES2917982T3 (es) 2022-07-12

Family

ID=50826043

Family Applications (1)

Application Number Title Priority Date Filing Date
ES15735507T Active ES2917982T3 (es) 2014-01-10 2015-01-07 Método para tratar trastornos hepáticos

Country Status (10)

Country Link
US (2) US8962687B2 (enExample)
EP (1) EP3091972B1 (enExample)
JP (2) JP2017502056A (enExample)
KR (1) KR102352729B1 (enExample)
CN (1) CN105934243A (enExample)
BR (1) BR112016015712A8 (enExample)
CA (1) CA2935933C (enExample)
ES (1) ES2917982T3 (enExample)
TW (1) TW201609081A (enExample)
WO (1) WO2015105874A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2950909C (en) * 2014-06-02 2023-03-28 Medicinova, Inc. Method of inhibiting or treating fibrosis
WO2016085994A1 (en) * 2014-11-26 2016-06-02 Medicinova, Inc. Ibudilast and telmisartan for treating non-alcoholic fatty liver disease, non alcoholic steatohepatitis, and advanced non alcoholic steatohepatitis
KR102399254B1 (ko) 2016-09-28 2022-05-17 아이거 바이오파마슈티컬스 인코포레이티드 비-알코올성 지방간염의 치료를 위한 방법 및 약제학적 조성물
CN110099690B (zh) * 2017-11-30 2021-10-26 北京通复堂生物科技股份有限公司 适于非酒精性脂肪性肝病和/或非酒精性脂肪性肝炎和/或肝脂肪变性的治疗的复方制剂
JP2024522030A (ja) * 2021-05-28 2024-06-10 メディシノバ・インコーポレイテッド フェノキシアルキルカルボン酸誘導体、およびトリグリセリドレベルを低下させることにおけるその使用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2585246A1 (fr) 1985-07-26 1987-01-30 Cortial Procede d'obtention de formes pharmaceutiques solides a liberation prolongee
US4788055A (en) 1985-12-09 1988-11-29 Ciba-Geigy Corporation Resinate sustained release dextromethorphan composition
GB8613688D0 (en) 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
GB8613689D0 (en) 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
US4816264A (en) 1986-06-06 1989-03-28 Warner-Lambert Company Sustained release formulations
FI76778C (fi) 1986-09-22 1988-12-12 Kyro Oy Foerfarande och anordning foer transport av glasskivor under upphettning och haerdning.
US4985585A (en) 1988-03-07 1991-01-15 Kyorin Pharmaceutical Co., Ltd. Phenoxyalkylcarboxylic acid derivatives and process for their preparations
US4996047A (en) 1988-11-02 1991-02-26 Richardson-Vicks, Inc. Sustained release drug-resin complexes
CA2002492A1 (en) 1988-11-11 1990-05-11 Sandra T. A. Malkowska Pharmaceutical ion exchange resin composition
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5290812A (en) 1991-01-18 1994-03-01 Kyorin Pharmaceutical Co., Ltd. Phenoxyalkylcarboxylic acid derivatives and process of preparing the same
US7060854B2 (en) 2003-06-24 2006-06-13 Medicinova, Inc. Process for making polymorphic form A of 4-[6-acetyl-3-[3-(4-acetyl-3-hydroxy-2-propylphenylthio)propoxy]-2-propylphenoxy]butyric acid
US7064146B2 (en) 2003-06-24 2006-06-20 Medicinova, Inc. Pharmaceutical compositions of isolated orthorhombic crystalline 4-[6-acetyl-3-[3-(4-acetyl-3-hydroxy-2-propylphenylthio)propoxy]-2-propylphenoxy]butyric acid and methods of use
US8835499B2 (en) 2011-12-08 2014-09-16 Medicinova, Inc. Method of treating non-alcoholic fatty liver disease and steatohepatitis

Also Published As

Publication number Publication date
EP3091972B1 (en) 2022-06-01
CA2935933A1 (en) 2015-07-16
JP2019218379A (ja) 2019-12-26
KR102352729B1 (ko) 2022-01-18
JP2017502056A (ja) 2017-01-19
US20150209314A1 (en) 2015-07-30
CA2935933C (en) 2022-06-28
WO2015105874A1 (en) 2015-07-16
EP3091972A4 (en) 2017-08-23
US8962687B2 (en) 2015-02-24
BR112016015712A2 (pt) 2017-08-08
KR20160099716A (ko) 2016-08-22
EP3091972A1 (en) 2016-11-16
TW201609081A (zh) 2016-03-16
BR112016015712A8 (pt) 2018-04-17
US20140155484A1 (en) 2014-06-05
CN105934243A (zh) 2016-09-07

Similar Documents

Publication Publication Date Title
ES2865505T3 (es) Composiciones y métodos para tratar la hiperpermeabilidad intestinal
ES2917982T3 (es) Método para tratar trastornos hepáticos
ES2402907T3 (es) Roscovitina para el tratamiento de ciertas enfermedades quísticas
US20230014055A1 (en) Treatment of Immune-Related Disorders, Kidney Disorders, Liver Disorders, Hemolytic Disorders, and Oxidative Stress-Associated Disorders Using NRH, NARH and Reduced Derivatives Thereof
US20150005385A1 (en) Method of treating non-alcoholic fatty liver disease and steatohepatitis
ES2964286T3 (es) Método de tratamiento de la Esteatohepatitis no alcohólica avanzada
ES2792850T3 (es) Método para tratar la fibrosis pulmonar idiopática
ES2957213T3 (es) Método para inhibir o tratar la fibrosis
US20150320705A1 (en) Method of inhibiting or treating amyotrophic lateral sclerosis with phenoxyalkylcarboxylic acids
WO2018192469A1 (en) Inhibitors of fabp4 and methods of treating arthritis
CN113827585B (zh) 艾地苯在治疗肢带型肌营养不良2g型中的应用
US20250223560A1 (en) Nox4 inhibitor compositions and methods for regeneration of dystrophic muscle
CN115381820A (zh) 盐酸去亚甲基四氢小檗碱在制备治疗溃疡性结肠炎药物中的应用
HK40086837A (zh) 用於预防或治疗肠炎和肠癌的药物
CN106474126B (zh) 抗癌小分子化合物索拉非尼在治疗肝包虫病中的应用
BR122025009675A2 (pt) Usos de ácido 15-hidroxi-eicosapentaenoico (15-hepe) para o tratamento ou prevenção de distúrbios hematológicos e/ou doenças relacionadas